ICD-10-PCS Codes

• 1 3E04002 (INTRODUCTION OF HIGH-DOSE INTERLEUKIN-2 INTO CENTRAL VEIN, OPEN APPROACH)

• 2 3E04003 (INTRODUCTION OF LOW-DOSE INTERLEUKIN-2 INTO CENTRAL VEIN, OPEN APPROACH)

• 3 3E04005 (INTRODUCTION OF OTHER ANTINEOPLASTIC INTO CENTRAL VEIN, OPEN APPROACH)

• 4 3E0400M (INTRODUCTION OF ANTINEOPLASTIC, MONOCLONAL ANTIBODY, INTO CENTRAL VEIN, OPEN APPROACH)

• 5 3E0400P (INTRODUCTION OF CLOFARABINE INTO CENTRAL VEIN, OPEN APPROACH)

• 6 3E04016 (INTRODUCTION OF RECOMBINANT HUMAN-ACTIVATED PROTEIN C INTO CENTRAL VEIN, OPEN)

• 7 3E04017 (INTRODUCTION OF OTHER THROMBOLYTIC INTO CENTRAL VEIN, OPEN APPROACH)

• 8 3E04028 (INTRODUCTION OF OXAZOLIDINONES INTO CENTRAL VEIN, OPEN APPROACH)

• 9 3E04029 (INTRODUCTION OF OTHER ANTI-INFECTIVE INTO CENTRAL VEIN, OPEN APPROACH)

• 10 3E0403Z (INTRODUCTION OF ANTI-INFLAMMATORY INTO CENTRAL VEIN, OPEN APPROACH)

• 11 3E0404Z (INTRODUCTION OF SERUM, TOXOID AND VACCINE INTO CENTRAL VEIN, OPEN APPROACH)

• 12 3E0406Z (INTRODUCTION OF NUTRITIONAL SUBSTANCE INTO CENTRAL VEIN, OPEN APPROACH)

• 13 3E0407Z (INTRODUCTION OF ELECTROLYTIC AND WATER BALANCE SUBSTANCE INTO CENTRAL VEIN, OPEN APPROACH)

• 14 3E040FZ (INTRODUCTION OF INTRACIRCULATORY ANESTHETIC INTO CENTRAL VEIN, OPEN APPROACH)

• 15 3E040GC (INTRODUCTION OF OTHER THERAPEUTIC SUBSTANCE INTO CENTRAL VEIN, OPEN APPROACH)

• 16 3E040GN (INTRODUCTION OF BLOOD BRAIN BARRIER DISRUPTION SUBSTANCE INTO CENTRAL VEIN, OPEN APPROACH)

• 17 3E040HZ (INTRODUCTION OF RADIOACTIVE SUBSTANCE INTO CENTRAL VEIN, OPEN APPROACH)

• 18 3E040KZ (INTRODUCTION OF OTHER DIAGNOSTIC SUBSTANCE INTO CENTRAL VEIN, OPEN APPROACH)

• 19 3E040NZ (INTRODUCTION OF ANALGESICS, HYPNOTICS, SEDATIVES INTO CENTRAL VEIN, OPEN APPROACH)

• 20 3E040PZ (INTRODUCTION OF PLATELET INHIBITOR INTO CENTRAL VEIN, OPEN APPROACH)

• 21 3E040RZ (INTRODUCTION OF ANTIARRHYTHMIC INTO CENTRAL VEIN, OPEN APPROACH)

• 22 3E040TZ (INTRODUCTION OF DESTRUCTIVE AGENT INTO CENTRAL VEIN, OPEN APPROACH)

• 23 3E040VG (INTRODUCTION OF INSULIN INTO CENTRAL VEIN, OPEN APPROACH)

• 24 3E040VH (INTRODUCTION OF HUMAN B-TYPE NATRIURETIC PEPTIDE INTO CENTRAL VEIN, OPEN APPROACH)

• 25 3E040VJ (INTRODUCTION OF OTHER HORMONE INTO CENTRAL VEIN, OPEN APPROACH)

• 26 3E040WK (INTRODUCTION OF IMMUNOSTIMULATOR INTO CENTRAL VEIN, OPEN)

• 27 3E040WL (INTRODUCTION OF IMMUNOSUPPRESSIVE INTO CENTRAL VEIN, OPEN)

• 28 3E040XZ (INTRODUCTION OF VASOPRESSOR INTO CENTRAL VEIN, OPEN APPROACH)

• 29 3E04302 (INTRODUCTION OF HIGH-DOSE INTERLEUKIN-2 INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 30 3E04303 (INTRODUCTION OF LOW-DOSE INTERLEUKIN-2 INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 31 3E04305 (INTRODUCTION OF OTHER ANTINEOPLASTIC INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 32 3E0430M (INTRODUCTION OF ANTINEOPLASTIC, MONOCLONAL ANTIBODY, INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 33 3E0430P (INTRODUCTION OF CLOFARABINE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 34 3E04316 (INTRODUCTION OF RECOMBINANT HUMAN-ACTIVATED PROTEIN C INTO CENTRAL VEIN, PERCUTANEOUS)

• 35 3E04317 (INTRODUCTION OF OTHER THROMBOLYTIC INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 36 3E04328 (INTRODUCTION OF OXAZOLIDINONES INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 37 3E04329 (INTRODUCTION OF OTHER ANTI-INFECTIVE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 38 3E0433Z (INTRODUCTION OF ANTI-INFLAMMATORY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 39 3E0434Z (INTRODUCTION OF SERUM, TOXOID AND VACCINE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 40 3E0436Z (INTRODUCTION OF NUTRITIONAL SUBSTANCE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 41 3E0437Z (INTRODUCTION OF ELECTROLYTIC AND WATER BALANCE SUBSTANCE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 42 3E043FZ (INTRODUCTION OF INTRACIRCULATORY ANESTHETIC INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 43 3E043GC (INTRODUCTION OF OTHER THERAPEUTIC SUBSTANCE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 44 3E043GN (INTRODUCTION OF BLOOD BRAIN BARRIER DISRUPTION SUBSTANCE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 45 3E043GQ (INTRODUCTION OF GLUCARPIDASE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 46 3E043GR (INTRODUCTION OF OTHER THERAPEUTIC MONOCLONAL ANTIBODY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 47 3E043HZ (INTRODUCTION OF RADIOACTIVE SUBSTANCE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 48 3E043KZ (INTRODUCTION OF OTHER DIAGNOSTIC SUBSTANCE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 49 3E043NZ (INTRODUCTION OF ANALGESICS, HYPNOTICS, SEDATIVES INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 50 3E043PZ (INTRODUCTION OF PLATELET INHIBITOR INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 51 3E043RZ (INTRODUCTION OF ANTIARRHYTHMIC INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 52 3E043TZ (INTRODUCTION OF DESTRUCTIVE AGENT INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 53 3E043VG (INTRODUCTION OF INSULIN INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 54 3E043VH (INTRODUCTION OF HUMAN B-TYPE NATRIURETIC PEPTIDE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 55 3E043VJ (INTRODUCTION OF OTHER HORMONE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)

• 56 3E043WK (INTRODUCTION OF IMMUNOSTIMULATOR INTO CENTRAL VEIN, PERCUTANEOUS)

• 57 3E043WL (INTRODUCTION OF IMMUNOSUPPRESSIVE INTO CENTRAL VEIN, PERCUTANEOUS)

• 58 3E043XZ (INTRODUCTION OF VASOPRESSOR INTO CENTRAL VEIN, PERCUTANEOUS APPROACH)